Cencora's Q3 revenue slightly beats estimates on Healthcare Solutions growth
Cencora's Q3 revenue slightly beats estimates on Healthcare Solutions growth
Overview
Pharmaceutical solutions provider's fiscal Q3 revenue grew 5.1% yr/yr, slightly beating analyst expectations
Adjusted EPS for fiscal Q3 rose 12% to $4.48, beating analyst expectations
Company repurchased $1 bln of shares during the quarter
Outlook
Cencora raises fiscal 2026 adj diluted EPS guidance to $17.75-$17.95
Cencora sees fiscal 2026 adj operating income growth of 13% to 14%
Result Drivers
SEGMENT GROWTH - Revenue growth was primarily driven by a 4.9% increase in U.S. Healthcare Solutions and a 5.9% increase in International Healthcare Solutions
GLP-1 SALES IMPACT - Increased sales of GLP-1s supported revenue growth but weighed on gross profit margins
Company press release: ID:nBw3x3WQ8a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $84.75 bln | $84.31 bln (11 Analysts) |
Q3 Adjusted EPS | Beat | $4.48 | $4.35 (13 Analysts) |
Q3 EPS |
| $3.94 |
|
Q3 Net Income |
| $776.67 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cencora, Inc. is $346.00, about 13% above its August 4 closing price of $306.28
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago
Reuters Recommended Reads
Aug 5 - CVS raises annual profit forecast on improved drug revenues
Aug 3 - Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Aug 3 - Obesity battle heats up again as Novo claws way back into race with Lilly
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)